Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lamivudine 150 mg vs Epivir in Healthy Volunteers
NCT02604004Phase 1Completed
- Sponsor
- Universidade Federal de Pernambuco
- Start
- Apr 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Universidade Federal de Pernambuco. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 36 hours. Started Apr 2013; status: completed.
02
Drugs
lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02604004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604004.